Coagulation dysfunction significantly impacts sepsis prognosis. Standardized methods for evaluating anticoagulant efficacy and safety in this population remain lacking. This study aimed to assess the efficacy and safety of anticoagulant therapy in sepsis patients.

Over the past few years, a growing number of knee arthroscopy (KA) procedures have been associated with an escalating incidence of postoperative venous thromboembolism (VTE), posing a significant threat to patient well-being. Nevertheless, the purpose of this study is to evaluate and synthesize the risk factors associated with VTE following KA, thereby establishing a scientific foundation for developing evidence-based clinical preventive measures.

Cancer, particularly gastrointestinal cancer, is associated with a higher risk of venous thromboembolism. Recent studies have increasingly compared direct oral anticoagulants (DOACs) with low molecular weight heparin (LMWH) for treating venous thromboembolism (VTE) in patients with gastrointestinal cancer. This meta-analysis aimed to investigate the efficacy of DOACs compared to LMWH for VTE in patients with gastrointestinal cancer.

Plasma coagulation factor XIII (OMIM#134570 (F13A1) and 134580(F13B), synthesized in haematopoietic cells (FXIII-A) and hepatocytes (FXIII-B); stabilizes and protects fibrin clots against fibrinolytic breakdown, ensuring haemostasis. Inherited FXIII deficiency is a rare inherited autosomal recessive bleeding disorder affecting 1-3 million people globally and demonstrating strong consanguinity contributing to high incidence of cases in Pakistan. Patients manifesting severe illness are homozygotes or compound heterozygotes.

Sickle cell disease is a hemoglobinopathy characterized by alterations in the components of hemostasis. Despite efforts and individual and multiple studies carried out to understand the pathophysiology of the disease, particularly regarding abnormalities of hemostasis and coagulation, questions remain. This meta-analysis aimed to evaluate the studies linking inflammatory, coagulation, and fibrinolysis abnormalities in sickle cell patients, putting them in an intrinsic state of hypercoagulability and predisposing them to thrombotic risk.

Haemophilia, caused by deficiencies in factor VIII or IX, leads to deep tissue bleeding and haemophilic arthropathy. Bleeding, arthropathy, and the perioperative period of surgery for arthropathy are associated with severe pain. To avoid this pain, patients may compensate by overloading other parts of the body, potentially resulting in pain or secondary damage in areas distant from the primary site. This study investigates the use of infrared thermography (IRT) to monitor whole-body surface temperatures in people with haemophilia and to explore the potential of infrared thermography for early detection of compensatory overload.

Asundexian, a novel oral Factor XIa (FXIa) inhibitor, targets the intrinsic coagulation pathway to prevent thrombosis while potentially reducing bleeding risk compared to direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs). This systematic review synthesizes clinical evidence on its safety, efficacy, and pharmacological properties in managing arterial and venous thrombotic events.

Accurate coagulation parameter reference intervals are crucial for diagnosing bleeding disorders and thromboembolic diseases. However, reference intervals vary across populations due to genetic, environmental, and demographic factors. This study aimed to establish localized coagulation reference intervals for healthy adults of Debre Berhan, Northeast Ethiopia, addressing the current reliance on non-local values.

Cancer-associated thrombosis (CAT), especially venous thromboembolism (VTE), is the second highest cause of mortality in cancer patients, following the cancer itself. Notably, among patients with thrombosis, cancer is the most common underlying cause of death, highlighting the strong interrelationship between these conditions. Tumour cells primarily promote a prothrombotic environment through activation of procoagulant properties of the host cells. Additionally, chemotherapy, radiotherapy and hormone treatments may amplify the thrombotic risk in cancer patients. Consequently, both arterial thromboses, including myocardial infarction (MI) and ischemic stroke (IS), and venous thrombosis, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), are significantly more prevalent among patients with malignancies. This review will discuss the association between cancer and thrombosis, illustrate the most common risk factors and discuss the direct and indirect molecular mechanisms involved.

Inherited platelet disorders are a heterogeneous group of rare conditions characterized by impaired platelet production or function, often leading to significant bleeding complications. Accurate diagnosis is essential for effective management and improved patient outcomes. However, the complexity of these disorders, coupled with the reliance on sophisticated diagnostic technologies, presents substantial challenges, particularly in settings with limited resources.

Critically ill patients are at high risk for venous thromboembolism (VTE). In non-Caucasian patients, routine thromboprophylaxis is controversial. No standard guidelines exist for critically ill Thai patients.

Factor V Leiden is classically linked to venous thrombosis, however arterial events in carriers are uncommon and usually context dependent.

Hereditary antithrombin deficiency (HATD) is a rare disease caused by mutations in the SERPINC1 gene characterized with venous thromboembolism and/or arterial thrombotic events. We identified a proband with recurrent arterial and venous thrombosis at multiple anatomical sites and subsequently performed comprehensive thrombophilia screening and genetic analysis within the kindred.

Anticoagulant therapy is considered useful for sepsis patients with disseminated intravascular coagulation (DIC); however, the efficacy of combination therapy with anticoagulants is still under investigation.

A 41 year old female with congenital thrombotic thrombocytopenic purpura (cTTP) underwent a total hip arthroplasty under prophylaxis with recombinant ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13). The procedure was performed without complications 12 h after the last injection. Postoperative ADAMTS13 activity levels showed a more rapid decrease in activity and in the individual apparent half-life due to increased consumption of the recombinant protease that could safely be managed by an intensified dosing regimen.

The optimal dosing strategy for recombinant human soluble thrombomodulin (rhTM) in clinical practice for sepsis-induced disseminated intravascular coagulation (DIC) has not been comprehensively evaluated. This study aimed to investigate whether different rhTM dosing strategies influence mortality outcomes in patients with sepsis-induced DIC.

Central venous catheter (CVC)-related thrombosis (CRT) has become a common iatrogenic complication in burn patients. Early and precise prediction is the foundations of effective prevention of CRT. However, there is not specific tool to predict CRT in burn populations. This study aimed to investigate the risk factors of CRT and develop a prediction model for CRT in burn populations.